Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Authors
Keywords
-
Journal
Medicina-Lithuania
Volume 55, Issue 10, Pages 698
Publisher
MDPI AG
Online
2019-10-17
DOI
10.3390/medicina55100698
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer
- (2019) Letizia Porcelli et al. Cancers
- Combined immune checkpoint inhibition (ICI) with tremelimumab and durvalumab in patients with advanced hepatocellular carcinoma (HCC) or biliary tract carcinomas (BTC).
- (2019) Charalampos S. Floudas et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
- (2019) Josep M Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review
- (2019) Vito Longo et al. Cancers
- Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study
- (2019) Antonella Argentiero et al. Cancers
- LBA15_PRA phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
- (2019) K Fizazi et al. ANNALS OF ONCOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting VEGF/VEGFR to Modulate Antitumor Immunity
- (2018) Ju Yang et al. Frontiers in Immunology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).
- (2018) Stacey Stein et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).
- (2018) Masafumi Ikeda et al. JOURNAL OF CLINICAL ONCOLOGY
- Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients
- (2018) Patrizia Leone et al. OncoImmunology
- Immunotherapy for colorectal cancer: where are we heading?
- (2017) Debora Basile et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Immunotherapeutic approaches for hepatocellular carcinoma
- (2017) Vito Longo et al. Oncotarget
- Cancer-associated fibroblasts in hepatocellular carcinoma
- (2016) Norio Kubo et al. WORLD JOURNAL OF GASTROENTEROLOGY
- The role of tumor microenvironment in therapeutic resistance
- (2016) Beomseok Son et al. Oncotarget
- Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
- (2016) Andrea Casadei Gardini et al. Oncotarget
- Liver sinusoidal endothelial cells induce immunosuppressive IL-10-producing Th1 cells via the Notch pathway
- (2015) Katrin Neumann et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib
- (2015) Andrea Casadei Gardini et al. EXPERT OPINION ON PHARMACOTHERAPY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies
- (2015) Gaetano Bertino et al. Biomed Research International
- Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
- (2013) Fumitaka Arihara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Randomized, Multicenter, Open-Label Study of Oxaliplatin Plus Fluorouracil/Leucovorin Versus Doxorubicin As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma From Asia
- (2013) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- An evolving new paradigm: endothelial cells – conditional innate immune cells
- (2013) Jietang Mai et al. Journal of Hematology & Oncology
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Immunotherapeutic Approaches to Hepatocellular Carcinoma Treatment
- (2012) Alexander G. Miamen et al. Liver Cancer
- Immunomodulatory effects of VEGF: Clinical implications of VEGF-targeted therapy in human cancer
- (2010) Giovanni Vitale et al. CANCER BIOLOGY & THERAPY
- EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence
- (2010) Anna Elisa Quatrale Frontiers in Bioscience-Landmark
- Tumor-infiltrating lymphocytes and hepatocellular carcinoma: pathology and clinical management
- (2010) Ken Shirabe et al. International Journal of Clinical Oncology
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade
- (2009) Nobuhiro Nakamoto et al. PLoS Pathogens
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now